Determination of Regulatory Review Period for Purposes of Patent Extension; AUCATZYL
Health and Human Services Department, Food and Drug Administration
About this archived opportunity
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AUCATZYL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Historical details
- Status
- Closed
- Deadline
- April 14, 2026
- First captured
- February 14, 2026
- Publisher reference
- 2026-02972
Eligibility: Business
This opportunity has closed
Determination of Regulatory Review Period for Purposes of Patent Extension; AUCATZYL
by Health and Human Services Department, Food and Drug Administration
Get notified when similar opportunities open
We'll save this search and email you when new determination, regulatory, review opportunities are posted. Free.